Table 3 Diagnostic performances of the SUV parameters at 18F-Alfatide PET/CT in patients with NSCLC.
NSCLC | Sensitivity | Specificity | PPV | NPV | Accuracy | |||||
|---|---|---|---|---|---|---|---|---|---|---|
% | 95%CI | % | 95%CI | % | 95%CI | % | 95%CI | % | 95%CI | |
Visual | 100.0 | 83.2–100 | 94.9 | 90.5–97.6 | 69.0 | 49.2–84.7 | 100 | 97.8–100 | 95.4 | 91.5–97.9 |
SUVmax | 90.0 | 68.3–98.2 | 96.0 | 92.0–98.4 | 72.0 | 50.6–87.93 | 98.8 | 95.4–99.9 | 95.4 | 91.5–97.9 |
SUVmean | 85.0 | 62.1–96.8 | 92.1 | 87.0–95.6 | 54.8 | 36.0–72.7 | 98.2 | 94.8–99.62 | 91.3 | 86.5–94.9 |
SUVLN/PT | 85.0 | 62.1–96.8 | 81.2 | 75.3–87.2 | 34.7 | 21.7–49.6 | 98.0 | 94.2–99.6 | 82.1 | 76.1–87.2 |
SUVLN/MBP | 85.0 | 62.1–96.8 | 96.0 | 92.0–98.4 | 70.8 | 48.9–87.4 | 98.3 | 95.0–99.6 | 94.9 | 90.8–97.5 |
SUVLN/M | 100.0 | 83.2–100 | 89.2 | 83.7–93.4 | 51.3 | 34.8–67.6 | 100 | 97.7–100 | 90.3 | 85.3–94.1 |
